How big is the dysautonomia (autonomic dysfunction) market today, and what are its future growth expectations?
The dysautonomia (autonomic dysfunction) market size has grown rapidly in recent years. It will grow from $2.62 billion in 2024 to $2.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to the increasing prevalence of autonomic disorders, growing awareness of dysautonomia, rising healthcare expenditure, expanding research in neurodegenerative diseases, and rising government support for rare diseases.
The dysautonomia (autonomic dysfunction) market size is expected to see rapid growth in the next few years. It will grow to $4.53 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to the growing adoption of personalized medicine, increasing clinical trials for novel treatments, rising government funding for rare disease research, expanding telemedicine and remote monitoring solutions, and increasing availability of orphan drugs. Major trends in the forecast period include the integration of artificial intelligence in diagnostics, the development of targeted therapies, the adoption of wearable devices for autonomic monitoring, advancements in gene therapies, and innovation in patient-centric treatment approaches.
Get Your Free Sample of The Global Dysautonomia (Autonomic Dysfunction) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21177&type=smp
What have been the primary factors driving the dysautonomia (autonomic dysfunction) market’s growth?
The increasing prevalence of chronic diseases is expected to propel the growth of the dysautonomia (autonomic dysfunction) market going forward. Chronic disease is a chronic condition or chronic sickness, a health condition that persists or lasts for over three months. The rise in chronic disease is due to factors such as increased frequency of multimorbidity, in which people are diagnosed with many chronic disorders at the same time. Dysautonomia (autonomic dysfunction) plays a crucial role in chronic diseases by disrupting the body’s ability to regulate essential functions like heart rate, blood pressure, and digestion, often exacerbating symptoms and complicating management. For instance, in October 2023, according to a report from the National Health Service, a UK-based healthcare system, the prevalence of Type 1 diabetes in England increased from 261,710 cases in 2020-21 to 270,935 cases in 2021-22, reflecting a growth of 3.5% year-over-year. Therefore, the increasing prevalence of chronic diseases is driving the growth of the dysautonomia (autonomic dysfunction) market.
Rising Autoimmune And Neurological Disorders Driving The Market Growth
An increase in autoimmune and neurological disorders is expected to propel the growth of the dysautonomia (autonomic dysfunction) market going forward. Autoimmune and neurological disorders are conditions where the immune system mistakenly attacks the body’s nervous system, leading to inflammation, damage, and dysfunction in the brain, spinal cord, or peripheral nerves. The increase in autoimmune and neurological disorders is driven by factors such as genetic predisposition, environmental triggers, lifestyle changes, infections, and improved diagnostic capabilities. Dysautonomia (autonomic dysfunction) serves as a critical indicator of underlying autoimmune and neurological disorders, as its presence in conditions like Sj?gren’s syndrome, multiple sclerosis, Parkinson’s disease, and multiple system atrophy (MSA) helps clinicians identify, monitor, and manage disease progression while tailoring targeted treatment approaches. For instance, in July 2023, according to the data from Public Health Scotland, a Scotland-based agency for improving and protecting health, in 2022, newly diagnosed patients with multiple sclerosis increased to 87.2%, up from 85.7% in the last two years, with 491 new cases reported, bringing the total to 6,359 in 2022. Therefore, an increase in autoimmune and neurological disorders will propel the growth of the dysautonomia (autonomic dysfunction) market.
What are the key segments within the dysautonomia (autonomic dysfunction) market?
The dysautonomia (autonomic dysfunction) market covered in this report is segmented –
1) By Type: Neurogenic Orthostatic Hypotension (NOH), Postural Orthostatic Tachycardia Syndrome (POTS), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Other Types
2) By Tests: Cardiovagal and Vasomotor Function Tests, Thermoregulatory Sweat Test (TST), Sympathetic Skin Response (SSR), Quantitative Sudomotor Axon Reflex Test, Other Tests
3) By Treatment: Physical Therapy, Exercise Therapy, Counseling, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Clinics, Diagnostic Centers, Research Institutes
Subsegments:
1) By Neurogenic Orthostatic Hypotension (NOH): Primary NOH, Secondary NOH (due to Parkinson’s Disease, Diabetes, etc.), Pharmacological Management of NOH, Non-Pharmacological Interventions
2) By Postural Orthostatic Tachycardia Syndrome (POTS): Hyperadrenergic POTS, Hypovolemic POTS, Neuropathic POTS, Autoimmune POTS, Treatment With Beta-Blockers, Fludrocortisone, And Salt Supplements
3) By Multiple System Atrophy (MSA): MSA-P (Parkinsonism), MSA-C (Cerebellar), MSA-A (Autonomic), Disease-Modifying and Symptomatic Treatment
4) By Pure Autonomic Failure (PAF): Idiopathic PAF, Secondary PAF (due to neurodegenerative diseases), Autonomic Supportive Treatments
5) By Other Types: Familial Dysautonomia (FD), Diabetic Autonomic Neuropathy, Horner’s Syndrome, Autoimmune Autonomic Ganglionopathy, Chronic Fatigue Syndrome-related Dysautonomia
Order your report now for swift delivery
Which key players are shaping the dysautonomia (autonomic dysfunction) market?
Major companies operating in the dysautonomia (autonomic dysfunction) market are Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Cadila Healthcare Limited (Zydus Cadila), Lupin Limited, Nemours Children’s Health Delaware, Alnylam Pharmaceuticals Inc., Biohaven Pharmaceuticals Holding Company Ltd., Aurora Health Care Inc., Camber Pharmaceuticals Inc., Theravance Biopharma Inc., Tocris Bioscience, Celltex Therapeutics Corporation, DyAnsys Inc., Axplora Inc., MODAG GmbH, Inhibikase Therapeutics Inc., Mylan Pharmaceuticals Private Limited, Chelsea Therapeutics International Ltd.
How will emerging trends drive the dysautonomia (autonomic dysfunction) market throughout the forecast period?
Major companies operating in the dysautonomia (autonomic dysfunction) market are focusing on developing advancements in gene therapy, such as recombinant adeno-associated virus, to enhance the delivery of therapeutic genes to target cells, aiming to improve treatment outcomes for patients with various forms of dysautonomia. Recombinant adeno-associated virus (rAAV) is a modified virus used in gene therapy to deliver genetic material into cells without causing disease. For instance, in January 2025, Tikun Therapeutics Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for Orphan Drug and Rare Pediatric Disease Designations for rAAV2-U1a-hELP1 (a gene therapy for optic neuropathy in familial dysautonomia) and BPN-36964 (a small molecule splicing modulator for systemic FD treatment). These innovative therapies aim to address the underlying genetic causes of FD, offering potential long-term benefits over symptomatic management.
How do regional factors impact the dysautonomia (autonomic dysfunction) market, and which region is the largest contributor?
North America was the largest region in the dysautonomia (autonomic dysfunction) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dysautonomia (autonomic dysfunction) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Dysautonomia (Autonomic Dysfunction) Market Report 2025 Offer?
The dysautonomia (autonomic dysfunction) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Dysautonomia, or autonomic dysfunction, refers to a condition where the autonomic nervous system (ANS) does not function properly, affecting involuntary bodily functions such as heart rate, blood pressure, digestion, and temperature regulation. It can result from various causes, including genetic factors, injuries, or underlying health conditions, leading to symptoms like dizziness, fainting, and irregular heartbeat.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21177
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
